

Ref: FOI/GS/ID 5704

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone, Kent
ME16 9QQ

24 September 2019

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Bone Metastases.

You asked:

- 1. Within your health trust how many metastatic breast cancer patients are currently [within the past 6 months] being treated, with any therapy, surgery or palliative care.*
- 2. Within your health trust how many breast cancer patients are currently [within the past 6 months] being treated for bone metastases with the following treatments;*
 - a. disodium pamidronate (Aredia)*
 - b. ibandronic acid or ibandronate (Bondronat)*
 - c. sodium clodronate (Bonefos, Clasteon, Loron)*
 - d. zoledronic acid or zoledronate (Zometa)*
 - e. denosumab (Xgeva)*
- 3. Within your health trust how many breast cancer patients are currently [within the past 6 months] being treated with adjuvant therapy with the following treatments;*
 - a. disodium pamidronate (Aredia)*
 - b. ibandronic acid or ibandronate (Bondronat)*
 - c. sodium clodronate (Bonefos, Clasteon, Loron)*
 - d. zoledronic acid or zoledronate (Zometa)*
- 4. Within your health trust how many metastatic lung cancer patients are currently [within the past 6 months] being treated with any therapy, surgery or palliative care.*
- 5. Within your health trust how many lung cancer patients are currently [within the past 6 months] being treated for bone metastases with the following treatments;*
 - a. disodium pamidronate (Aredia)*
 - b. ibandronic acid or ibandronate (Bondronat)*
 - c. sodium clodronate (Bonefos, Clasteon, Loron)*

- d. zoledronic acid or zoledronate (Zometa)
 - e. denosumab (Xgeva)
6. Within your health trust how many metastatic renal cell cancer patients are currently [within the past 6 months] being treated with any therapy, surgery or palliative care.
7. Within your health trust how many renal cell carcinoma [RCC] patients are currently [within the past 6 months] being treated for bone metastases with the following treatments;
- a. disodium pamidronate (Aredia)
 - b. ibandronic acid or ibandronate (Bondronat)
 - c. sodium clodronate (Bonefos, Clasteon, Loron)
 - d. zoledronic acid or zoledronate (Zometa)
 - e. denosumab (Xgeva)

Trust response:

Please note the following important information.

- Q 1,4 and 6 include all patients with a primary diagnosis of breast, lung or kidney cancer (respectively) which has spread (has a M1 status) and treatment has started in the last 6 months. The Trust is unable to comment on ongoing treatments and if they are still continuing.
- Q 2, 5 and 7 include patients in in Q1,4 and 6 (respectively) with specifically bone metastases that have received one of the drugs where data which has been requested.
- Q3 includes all breast cancer patients undergoing subsequent treatment ('adjuvant').

1. 93

2.

- disodium pamidronate (Aredia) 0
- ibandronic acid or ibandronate (Bondronat) 0
- sodium clodronate (Bonefos, Clasteon, Loron) 0
- zoledronic acid or zoledronate (Zometa) 2
- denosumab (Xgeva) 8

3.

- disodium pamidronate (Aredia) 0
- ibandronic acid or ibandronate (Bondronat) 0
- sodium clodronate (Bonefos, Clasteon, Loron) 0
- zoledronic acid or zoledronate (Zometa) 48

4. 114

5.

- disodium pamidronate (Aredia) 0
- ibandronic acid or ibandronate (Bondronat) 0
- sodium clodronate (Bonefos, Clasteon, Loron) 0
- zoledronic acid or zoledronate (Zometa) 1
- denosumab (Xgeva) 1

6. 18

7.

- disodium pamidronate (Aredia) 0
- ibandronic acid or ibandronate (Bondronat) 0
- sodium clodronate (Bonefos, Clasteon, Loron) 0

- zoledronic acid or zoledronate (Zometa) 0
- denosumab (Xgeva) 1